Should You Buy Morepen Labs Stock in India in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Morepen Labs for over three years. Every month, over a million users in India trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, paid by Morepen Labs.

What is Morepen Labs?

Morepen Labs stock price

The price of Morepen Labs stock is rising this week. As of now, the current share price stands at ₹65.36, up by ₹1.42 (+2.22%) over the last 24 hours and showing a +4.14% gain over the week. The company’s market capitalization has reached ₹3,581 crores, with an average three-month daily trading volume of 4.62 million shares. Morepen Labs trades at a P/E Ratio of 30.4 and offers a modest dividend yield of 0.31%. The stock has a beta of 1.81, indicating a relatively high level of volatility in the Indian market. This performance highlights both active investor interest and the dynamic nature of the stock.

Our full analysis of the Morepen Labs stock

We have meticulously reviewed Morepen Labs’s most recent financial statements, along with its share price evolution and business performance over the past three years. By leveraging multiple sources—financial ratios, technical trends, market intelligence, and benchmarking against sector peers—our proprietary analysis provides a data-driven view of Morepen Labs’s current positioning and prospects. So, why might Morepen Labs stock once again become a strategic entry point into the Indian pharmaceutical and healthcare sector in 2025?

Recent performance and market context

Morepen Labs has demonstrated remarkable resilience and growth in its stock price, climbing to ₹65.36 as of the latest session. Over the past six months, the stock has gained 32.71%, with a solid 17.09% advance in the last year and a weekly move of +4.14%. The company’s current market capitalization stands at ₹3,581 crores, reflecting its status among India’s leading mid-cap pharma names. Recent positive developments include the successful launch of three new APIs (Rivaroxaban, Vildagliptin, and UDCA) and the creation of a wholly-owned Dubai subsidiary, bolstering Morepen Labs’s international reach. Sector-wide tailwinds—such as increased healthcare spending, supportive regulatory frameworks, and India’s ambition to strengthen its pharmaceutical exports—underline the favorable macro context for continued outperformance.

Technical analysis

On the technical front, Morepen Labs is exhibiting notable momentum. The current Relative Strength Index (RSI) is in the neutral to slightly bullish zone, in line with the sustained positive trend. The stock trades above its 20-, 50-, and 100-day moving averages (₹63.35, ₹62.83, and ₹56.79, respectively), signaling short- and medium-term technical strength, while facing modest resistance just below its 200-day average (₹67.73). Intraday movement of +2.22% and a weekly uptrend suggest ongoing accumulation by institutional and retail investors. Support levels are firmly established at ₹62.23–₹63.31, while overhead resistance lies at ₹65.02–₹67.81; a breakout above the latter would reinforce a bullish reversal pattern. The neutral-to-bullish technical stance, paired with strong volume, signals that the current price zone offers an attractive entry point for buyers who seek momentum-based exposure.

Fundamental analysis

Fundamentally, Morepen Labs stands out for its robust financial profile and growth orientation. Q4 FY25 revenue rose to ₹470.46 crores, up 10.1% year-over-year and in line with management’s double-digit guidance. While net profit in the latest quarter moderated to ₹20.31 crores due to higher input costs, EBITDA margin remains healthy at 9%, reflecting disciplined operating control. The company’s long-term debt-to-equity ratio is exceptionally low at 0.07, highlighting a strong balance sheet and financial flexibility. Valuation metrics, such as a P/E of 30.4 and a price-to-book ratio of 3.23, are consistent with a premium leadership position in the Indian API market and ongoing expansion into formulations and medical devices. Morepen Labs’s deep pipeline of innovation (including products for growing chronic and lifestyle diseases), its dominant export profile in over 80 countries, and world-class manufacturing infrastructure (USFDA-approved) provide a strategic edge few domestic competitors can match.

Volume and liquidity

Trading activity in Morepen Labs has remained robust, with an average 3-month daily volume of 4.62 million shares. Such sustained volume is a classic marker of heightened market confidence and liquidity, facilitating efficient price discovery and reducing entry/exit risk for both retail and institutional participants. The stable float—comprising a broad public holding (60.72%) and consistent promoter support (35.66%)—translates into a favorable shareholding structure for dynamic and sustained re-rating. Active daily participation ensures that technical breakouts are more reliable, reinforcing the stock’s candidacy for bullish medium-term positioning.

Catalysts and positive outlook

• Expansion of the sales force by over 1,000 medical representatives, powering deeper market penetration for its formulations business.
• Strategic spin-off of the medical devices division, unlocking additional value for shareholders through focused business segments.
• Continued leadership in six high-growth APIs, where it holds market shares between 19% and 70%—notably in Montelukast, Loratadine, and Desloratadine.
• Robust R&D pipeline with products tailored for export demand, ensuring resilience to domestic price pressures.
• Entry into new geographies with the Dubai subsidiary, enhancing access to lucrative MENA and European markets.
• Long-term management guidance targeting 10–15% annual growth through FY26, with a projected 17–18% CAGR over the next several years.
• Strong alignment with India’s “Pharma Vision” policy, as the company’s quality benchmarks, regulatory approvals, and export orientation support continued expansion.

Investment strategies

• Short-term: For tactical investors, current levels above ₹63—but still within reach of longer-term support—present a compelling technical entry, as momentum remains strong and near-term fundamental catalysts (new product launches, spin-off plans) are on the horizon.
• Medium-term: Persistent strength in API exports, combined with the commercial ramp-up of new formulations and medical devices, creates room for steady earnings recovery and outperformance against the sector composite, particularly as cost headwinds dissipate in the next few quarters.
• Long-term: With its established international network, class-leading manufacturing certifications, and an expanding share in fast-growing therapeutic areas, Morepen Labs seems ideally suited for a buy-and-hold strategy. Robust cash flows, prudent capital deployment, and a legacy of sustainable dividend payouts provide further comfort that the company’s growth ambition is backed by solid fundamentals.

Is it the right time to buy Morepen Labs?

In summary, Morepen Labs combines multiple layers of strength: robust sales growth, a strategic leadership position in APIs, innovative product development, and geographic diversification. Favorable technical signals, outstanding liquidity, and the prospect of upcoming catalysts reinforce the sense that the stock may be entering a new bullish phase. While short-term volatility is always an inherent feature of small- and mid-cap pharma, Morepen Labs’s fundamentals justify renewed interest. For investors looking to participate in India’s dynamic healthcare and pharmaceutical expansion, Morepen Labs seems to represent an excellent opportunity—supported by a blend of resilience, innovation, and scalable growth. The alignment of technical and fundamental drivers strengthens the conviction that Morepen Labs is well positioned for sustained value creation in the months and years to come.

How to buy Morepen Labs stock

Investing in Morepen Labs stock online is both simple and secure when using a regulated broker in India. Investors have two main choices: a spot (cash) purchase where you own real shares, or using Contracts for Difference (CFDs) to trade with leverage and flexibility. Both methods are available on user-friendly digital platforms, with your investments protected by local market rules. To compare which broker is right for your needs, see the comparison guide further down the page.

Spot buying

Spot (cash) buying of Morepen Labs stock means you purchase and own actual shares, typically listed on the NSE or BSE. Indian brokers usually charge a fixed commission per trade, often between ₹20 and ₹50, making it cost-effective for most investors.

Morepen Labs Share Investment: Gain Scenario

If the Morepen Labs share price is ₹65.36, you can buy around 15 shares with a $1,000 stake (at ₹83/$1), including a brokerage fee of around $5.
✔️ Gain scenario:
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD (Contract for Difference) trading on Morepen Labs allows you to benefit from price movements without owning the actual stock. CFD traders pay a spread (the broker’s margin between buy and sell prices) and may incur overnight financing costs for leveraged or long-term positions. The main attraction is the ability to use leverage, magnifying your exposure and potential returns.

CFD Gain Scenario with Leverage

You open a CFD position on Morepen Labs shares, with 5x leverage.

This gives you a market exposure of $5,000.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before investing, always compare the fees, features, and conditions offered by different brokers to make the best choice for your goals. Your decision between spot buying and CFD trading should be based on whether you want to hold shares long term or aim for short-term trading opportunities. For more details, check out the broker comparison further down this page.

Our 7 tips for buying Morepen Labs stock

The latest news about Morepen Labs

Morepen Labs posted a solid 4.14% weekly stock gain supported by positive investor sentiment. This uptick reflects investor confidence after the company reported revenue growth and demonstrated resilience in the pharmaceutical sector, especially considering strong results for the quarter ended March 2025.

The company has successfully expanded its sales division, adding 1,000 new representatives to boost its formulations business. This strategic hiring initiative directly positions Morepen Labs to accelerate domestic market penetration and strengthen its distribution network across India, aligning with management’s growth vision.

Key technical indicators are showing a neutral to slightly bullish trend, with the stock above its short-term averages. Morepen Labs now trades above its 20-, 50-, and 100-day moving averages, while remaining just under the 200-day average, suggesting steady upward momentum and technical support for continued appreciation.

Morepen Labs is launching three new high-potential APIs, targeting further leadership in the Indian and global markets. The development of Rivaroxaban, Vildagliptin, and UDCA expands the product pipeline and addressable pharmaceutical markets, strengthening future revenue potential.

The company’s planned spin-off of the medical devices division is set to unlock further shareholder value. Separating this business as a standalone entity allows dedicated capital allocation and strategic focus, which is likely to create new growth opportunities and could lead to market re-rating.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.